Fidelity Research and Management Company led a $51m equity financing for Outset Medical.

Fidelity Research and Management Company led a $51m equity financing for Outset Medical, a company focused on reimagining the experience of dialysis care for patients with kidney disease. “We are gratified by the strong showing of support from existing and new investors who share our vision of expanding where, how and who can perform hemodialysis,” said Leslie Trigg, Outset Medical’s CEO. “Today, hemodialysis is labor-intensive and expensive to provide, and many patients lack flexibility and control over the experience. Tablo uniquely enables new care delivery models that may offer significant cost reduction opportunities for providers while substantially improving the experience for patients.”